In September, Eli Lilly presented the results of its phase-3 Spartan trial, in which Lasmiditan demonstrated significant progress in the treatment of migraines.
In September 2017, Eli Lilly announced that a 12-month open-label study showed a positive safety and tolerability profile of Galcanezumab for migraines.
In 1H17, Eli Lilly’s (LLY) Alimta reported revenues of around $1.0 billion, compared with $1.2 billion in 1H16.
In 1H17, Eli Lilly’s (LLY) Cyramza reported revenues of around $357.5 million, compared with $278.0 million in 1H16.
In September, the FDA approved Eli Lilly’s (LLY) Verzenio-fulvestrant combination therapy for the treatment of women with hormone receptor-positive or HR+.
In 1H17, Eli Lilly (LLY) generated revenues of around $11.0 billion, compared with $10.3 billion in 1H16.
So far in October, of the 22 analysts covering Eli Lilly (LLY), four have suggested a “strong buy,” while ten analysts have suggested a “buy.”
According to analysts’ estimates, Intuitive Surgical is expected to post 3Q17 adjusted diluted EPS of $1.99.
Johnson & Johnson’s (JNJ) medical device business has been restructuring in order to focus on higher growth areas with potential expansion opportunities.
On October 12, 2017, Johnson & Johnson’s (JNJ) medical device subsidiary, Depuy Synthes, announced the launch of the company’s new TFNA Augmentation system in the United States.
Johnson & Johnson (JNJ) registered revenues of $18.8 billion, a YoY (year-over-year) increase of around 1.6% in 2Q17.
Johnson & Johnson (JNJ) will announce its 3Q17 earnings results on October 17, 2017.
According to recent Wall Street analysts’ estimates, Intuitive Surgical is expected to report revenues of $753.2 million in 3Q17. That represents a YoY sales growth of 10.3%.
Intuitive Surgical (ISRG) is set to announce its 3Q17 earnings results on October 19, 2017. Over the past few weeks, ISRG stock has risen to new highs.
In 3Q17, the Established Pharmaceuticals segment of Abbott Laboratories is expected to report high double-digit operational sales growth.
The 3Q17 EPS estimate for Abbott Laboratories is $0.65. The company has provided an EPS guidance range of $0.64–$0.66 for 3Q17.
Analysts expect Abbott Laboratories to report 3Q17 revenues of ~$6.7 billion, representing a YoY (year-over-year) growth of ~26.7%.
On October 18, 2017, Abbott Laboratories will release its 3Q17 earnings results. Abbott stock was trading at its 52-week high of $55.4 on October 10.
According to World Health Organization (or WHO), around 235 million individuals worldwide have asthma.
EVENITY (romosozumab) is a monoclonal antibody under investigation that acts by inhibiting the activity of sclerostin.